4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$6.60 USD
-0.50 (-7.04%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FDMT 6.60 -0.50(-7.04%)
Will FDMT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Other News for FDMT
Is FDMT preparing to trend lower? Fell Below 20 Day Moving Average shows up after crashing 7.04%
H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Crossed Above 20 Day Moving Average appears for FDMT after 6.61% move
FDMT forms 20 Day Moving Average Resistance on September 17
FDMT forms 1,2,3 Pullback Bullish on September 16